Abstract: The present invention relates to a method for preventing or treating a coronavirus infectious disease, comprising administering to a patient in need thereof a therapeutically or prophylactically effective amount of a compound represented by formula (I) or pharmaceutically acceptable salts thereof. The compound represented by formula (I) is used for treating patients with novel coronavirus pneumonia, and shows obvious advantages in all of the clearance rate by viral nucleic acid test, the course of clearance, and the cure and discharge time.

Abstract: The present invention discloses a crystal form, a preparation method and an application of a 4?-substituted nucleoside compound I having the following structure, including salts, prodrugs, and compositions thereof. Animal pharmacokinetic studies demonstrated that the effective drug concentrations of Compound Ia and Compound Ig in HIV target cells, peripheral blood mononuclear cells (PBMC), were effective in inhibiting HIV replication after 7 and 5 days, respectively. Therefore, Compound I can be used as a long-acting drug for preventing and treating AIDS. R is selected from ethynyl, azide, and cyano groups, X is selected from hydrogen and fluorine, and B is selected from B1 and B2.

Abstract: A compound represented by formula I or II. X represents a mono substituent on a benzene ring, and is selected from —H, —I, —Br, —Cl, —F, —CN, an amino, and a derivative thereof; R1 is a C2-10 alkyl, C2-10 alkyl substituted by cyclopropane or fluorine, except n-butyl; and M is an amine ion or metal ion.

Abstract: A 2-(2,4,5-substituted phenylamino) pyrimidine derivative, having the following chemical formula I:

Abstract: A crystalline form A of a compound I is a monoclinic system and a space group thereof is p21.

Abstract: The present invention discloses 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt in different crystal forms and the preparation methods thereof, and belongs to the field of pharmaceutical chemistry. Said different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt include: amorphous 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, crystal form A of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, and crystal form B of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt. The different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt obtained according to the present invention have better stability and water-solubility than the mixed forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, thus is advantageous for pharmaceutical use. Moreover, the different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt possess much better therapeutic effect than 5-bromo-2-(?-hydroxypentyl)benzoic acid potassium salt.

Abstract: The disclosure relates to a thienopyrimidinone derivative, or a pharmaceutically acceptable prodrug, salt, and solvate thereof. The derivative has the formula (I), where R represents hydrogen (H) or deuterium (D); R1 and R2 independently, at each occurrence, represent H, D, F, Cl, I, cyano group (CN), or N3, and when R represents H, R1 and R2 do not synchronously represent H; R3, R4 and R5 independently, at each occurrence, represent an alkyl group, a cycloalkyl group, a heterocyclic group, an aromatic ring group, or a heteroaryl ring group, which are substituted or unsubstituted.

Abstract: A compound represented by formula I or II. X represents a mono substituent on a benzene ring, and is selected from —H, —I, —Br, —Cl, —F, —CN, an amino, and a derivative thereof; R1 is a C2-10 alkyl, C2-10 alkyl substituted by cyclopropane or fluorine, except n-butyl; and M is an amine ion or metal ion.

Abstract: The present invention discloses 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt in different crystal forms and the preparation methods thereof, and belongs to the field of pharmaceutical chemistry. Said different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt include: amorphous 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, crystal form A of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, and crystal form B of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt. The different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt obtained according to the present invention have better stability and water-solubility than the mixed forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, thus is advantageous for pharmaceutical use. Moreover, the different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt possess much better therapeutic effect than 5-bromo-2-(?-hydroxypentyl)benzoic acid potassium salt.

Abstract: The disclosure relates to a thienopyrimidinone derivative, or a pharmaceutically acceptable prodrug, salt, and solvate thereof. The derivative has the formula (I), where R represents hydrogen (H) or deuterium (D); R1 and R2 independently, at each occurrence, represent H, D, F, Cl, I, cyano group (CN), or N3, and when R represents H, R1 and R2 do not synchronously represent H; R3, R4 and R5 independently, at each occurrence, represent an alkyl group, a cycloalkyl group, a heterocyclic group, an aromatic ring group, or a heteroaryl ring group, which are substituted or unsubstituted.

Abstract: The present invention discloses 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt in different crystal forms and the preparation methods thereof, and belongs to the field of pharmaceutical chemistry. Said different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt include: amorphous 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, crystal form A of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, and crystal form B of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt. The different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt obtained according to the present invention have better stability and water-solubility than the mixed forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, thus is advantageous for pharmaceutical use. Moreover, the different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt possess much better therapeutic effect than 5-bromo-2-(?-hydroxypentyl)benzoic acid potassium salt.

Abstract: The present invention discloses 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt in different crystal forms and the preparation methods thereof, and belongs to the field of pharmaceutical chemistry. Said different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt include: amorphous 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, crystal form A of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, and crystal form B of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt. The different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt obtained according to the present invention have better stability and water-solubility than the mixed forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, thus is advantageous for pharmaceutical use. Moreover, the different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt possess much better therapeutic effect than 5-bromo-2-(?-hydroxypentyl)benzoic acid potassium salt.

Abstract: The present invention discloses 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt in different crystal forms and the preparation methods thereof, and belongs to the field of pharmaceutical chemistry. Said different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt include: amorphous 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, crystal form A of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, and crystal form B of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt. The different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt obtained according to the present invention have better stability and water-solubility than the mixed forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, thus is advantageous for pharmaceutical use. Moreover, the different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt possess much better therapeutic effect than 5-bromo-2-(?-hydroxypentyl)benzoic acid potassium salt.

Abstract: The present invention discloses 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt in different crystal forms and the preparation methods thereof, and belongs to the field of pharmaceutical chemistry. Said different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt include: amorphous 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, crystal form A of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, and crystal form B of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt. The different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt obtained according to the present invention have better stability and water-solubility than the mixed forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, thus is advantageous for pharmaceutical use. Moreover, the different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt possess much better therapeutic effect than 5-bromo-2-(?-hydroxypentyl)benzoic acid potassium salt.

Abstract: The present invention discloses 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt in different crystal forms and the preparation methods thereof, and belongs to the field of pharmaceutical chemistry. Said different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt include: amorphous 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, crystal form A of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, and crystal form B of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt. The different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt obtained according to the present invention have better stability and water-solubility than the mixed forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, thus is advantageous for pharmaceutical use. Moreover, the different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt possess much better therapeutic effect than 5-bromo-2-(?-hydroxypentyl)benzoic acid potassium salt.

Abstract: The present invention relates to the field of pharmacochemistry. Disclosed are fluorinated and azido-substituted pyrimidine nucleoside derivatives, particularly compounds of the formula shown below: Also disclosed are methods of preparation and uses for these compounds. The compounds can be used for preparing medicaments for treating diseases such as tumors and viral infections, and can be used separately or in combination with other medicaments. The compounds also have effective activity against diseases such as tumors and viral infections, while having few side effects, and thus have potential application value.

Abstract: The present invention discloses 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt in different crystal forms and the preparation methods thereof, and belongs to the field of pharmaceutical chemistry. Said different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt include: amorphous 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, crystal form A of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, and crystal form B of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt. The different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt obtained according to the present invention have better stability and water-solubility than the mixed forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt, thus is advantageous for pharmaceutical use. Moreover, the different crystal forms of 5-bromo-2-(?-hydroxypentyl)benzoic acid sodium salt possess much better therapeutic effect than 5-bromo-2-(?-hydroxypentyl)benzoic acid potassium salt.

Abstract: This application discloses phosphoramidate and phosphonoamidate prodrugs of alcohol-based therapeutic agents, such as nucleosides, nucleotides, acyclonucleosides, C-nucleosides, and C-nucleotides, and use of these prodrugs for treatment of diseases or disorders, including infectious diseases and cancers. This application also discloses a general method for enhancing bioavailability and/or liver-targeting property of alcohol drugs through converting the alcohol drugs to phosphoramidate or phosphonoamidate prodrugs, and methods of preparation of these prodrugs.

Abstract: This application discloses novel phosphoramidate and phosphonoamidate prodrugs of nucleosides, nucleotides, C-nucleosides, C-nucleotides, phosphonates, and other alcohol-containing drugs; use of these prodrugs for treatment of infectious diseases and cancers, in particular, liver infections and cancers; and methods of preparing these novel phosphoramidate and phosphonoamidate prodrugs.

Abstract: The present invention is made to fulfill the foregoing need. Since most of antiHN nucleosides are 2?,3?-dideoxynucleosides that have been proved to be excellent substrates of kinases for the phosphorylations. 2?,3?-Dideoxy-2,-a-fluoro-2?-{3-C-methyl-nucleosides can be considered as one unique class of 2?,3?-dideoxynucleosides to be good substrate of kinases because fluorine mimics hydrogen. It also can be considered as ribo-nucleosides to incorporate into RNA of HCV because 2?-fluorine-a mimics 2?-a-OH group.